Vaccine trial, Phase 1, ongoing in Rhode Island for advanced prostate cancer patients. Posted April 20, 2009
PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study (Dendreon p-r) April 14, 2008
Dendreon announcement prior to AUA annual meeting. Posted April 20, 2009
CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer. Tuebingen (Germany), January 5, 2009.
Provenge prostate cancer vaccine linked to longer survival for asymptomatic hormone refractory stage -- UCSF study. June 28, 2006.
Provenge Vaccine "Significantly Improves" Survival In Men With Advanced Prostate Cancer February 17, 2005
Gvax Prostate Cancer Vaccine Demonstrates Antitumor Activity December 11, 2000
Vaccinia-based Vaccine Shows Promise for Treating Nonmetastatic Hormone Refractory Prostate Cancer July 2005
Vaccinia Virus and Fowlpox Vaccines in Phase II Trial for Prostate Cancer 2000; results - updated 2004
Adoptive Immunotherapy - Steps Toward Overcoming Biological Obstacles to Cell Therapy for Cancer February 16, 2006
Combination Hormone/Vaccine Therapy for Prostate Cancer May Benefit Patients Whose Disease Returns July 25, 2005
MICs shed light on prostate cancer August 16, 2004.
Counseling Boosts Immunity in Breast Cancer Patients September 22, 2004
Information on this website is not intended as medical advice nor to be taken as such. Consult qualified physicians specializing in the treatment of prostate cancer. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained on this website.